secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087001
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data
--------------------------------------------------------------------------------

- Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.
- Cash and equivalents $28.5M as of June 30, 2024; NIA grant funds remaining $57.3M.
- Net loss $7.0M for Q2 2024 vs $4.7M for Q2 2023.
- Topline results from SHIMMER study in DLB expected by year-end 2024.
- Company planning next phase of Alzheimer's development after SHINE results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924087001/0001104659-24-087001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924087001/tm2421054d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer